Milestone Pharmaceuticals Inc. (MIST) NASDAQ
1.90
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.90
+0(+0.00%)
Currency In USD
Address
1111 Dr. Frederik-Philips Boulevard
Montreal, QC H4M 2X6
Canada
Phone
15143360444
Sector
Healthcare
Industry
Biotechnology
Employees
33
First IPO Date
May 09, 2019
| Name | Title | Pay | Year Born |
| Joseph G. Oliveto | Chief Executive Officer, President & Director | 931,384 | 1968 |
| Lorenz Muller | Chief Commercial Officer | 397,534 | 1964 |
| Amit Hasija | Chief Financial Officer & Executive Vice President of Corporate Development | 631,860 | 1973 |
| David Bharucha FACC | Chief Medical Officer | 664,417 | 1962 |
| Philip T. Sager FACC FAHA FHRS | Chief Medical Advisor & Member of the Scientific Advisory Board | 0 | 1956 |
| Guy Rousseau | SVP of Regulatory Affairs and Quality Management | 0 | N/A |
| Philippe Douville | Founder, Strategic Advisor & Member of Scientific Advisory Board | 0 | 1962 |
| David Sandoval | General Counsel & Chief Compliance Officer | 0 | 1978 |
| Jeff Moore | Vice President of Sales | 0 | N/A |
| Jeff Nelson | Chief Operating Officer | 0 | 1981 |
| Roshan Girglani | Vice President of Marketing | 0 | N/A |
| Anita Holz | Vice President & Head of Medical Affairs | 0 | N/A |
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.